QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
Free Trial

Eli Lilly and Company (LLY) Stock Forecast & Price Target

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)
Free lly Stock Alerts
$745.95
-4.82 (-0.64%)
(As of 04:10 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Eli Lilly and Company Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 19 Analyst Ratings

Analysts' Consensus Price Target

$728.05
-2.40% Downside
High Forecast$1,000.00
Average Forecast$728.05
Low Forecast$458.00
TypeCurrent Forecast
4/19/23 to 4/18/24		1 Month Ago
3/20/23 to 3/19/24		3 Months Ago
1/19/23 to 1/19/24		1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
11 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$728.05$689.52$583.24$382.84
Predicted Upside-2.40% Downside11.56% Upside12.61% Upside9.47% Upside
Get Eli Lilly and Company Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

LLY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Company Stock vs. The Competition

TypeEli Lilly and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.84
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside-3.04% Downside934.30% Upside12.27% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/15/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$815.00+8.08%
4/11/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$650.00 ➝ $723.00-5.02%
4/3/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy
4/2/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$675.00 ➝ $895.00+17.15%
3/22/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$850.00+10.13%
3/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$775.00 ➝ $850.00+11.10%
3/1/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$800.00 ➝ $1,000.00+28.43%
2/21/2024DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$820.00+8.50%
2/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$805.00 ➝ $950.00+25.48%
2/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$680.00 ➝ $810.00+11.08%
2/7/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$710.00 ➝ $865.00+21.15%
2/6/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$700.00 ➝ $825.00+17.02%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold$535.00-13.64%
10/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$612.00 ➝ $710.00+20.28%
9/5/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$470.00 ➝ $620.00+10.67%
8/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%
8/8/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$408.00 ➝ $615.00+17.91%
8/8/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$560.00+28.82%
6/27/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains
6/20/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$375.00 ➝ $500.00+10.15%
5/1/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$410.00 ➝ $458.00+15.70%
4/28/20233M
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:41 PM ET.

LLY Price Target - Frequently Asked Questions

What is Eli Lilly and Company's consensus rating and price target?

According to the issued ratings of 19 analysts in the last year, the consensus rating for Eli Lilly and Company stock is Moderate Buy based on the current 3 hold ratings and 16 buy ratings for LLY. The average twelve-month price prediction for Eli Lilly and Company is $728.05 with a high price target of $1,000.00 and a low price target of $458.00. Learn more on LLY's analyst rating history.

Do Wall Street analysts like Eli Lilly and Company more than its competitors?

Analysts like Eli Lilly and Company more than other Medical companies. The consensus rating score for Eli Lilly and Company is 2.84 while the average consensus rating score for medical companies is 2.68. Learn more on how LLY compares to other companies.

Is Eli Lilly and Company being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Eli Lilly and Company's stock had 1 upgrade and 1 downgrade by analysts.

Does Eli Lilly and Company's stock price have much upside?

According to analysts, Eli Lilly and Company's stock has a predicted upside of 11.11% based on their 12-month stock forecasts.

What analysts cover Eli Lilly and Company?

Eli Lilly and Company has been rated by Bank of America, Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, DZ Bank, Erste Group Bank, JPMorgan Chase & Co., Morgan Stanley, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:LLY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative